US20090137416A1
(en)
|
2001-01-16 |
2009-05-28 |
Regeneron Pharmaceuticals, Inc. |
Isolating Cells Expressing Secreted Proteins
|
NZ570811A
(en)
|
2002-11-09 |
2009-11-27 |
Immunocore Ltd |
T cell receptor display
|
GB0304068D0
(en)
*
|
2003-02-22 |
2003-03-26 |
Avidex Ltd |
Substances
|
US20060047437A1
(en)
*
|
2004-08-25 |
2006-03-02 |
Ishikawa Muriel Y |
System and method for heightening an immune response
|
US20060047436A1
(en)
*
|
2004-08-25 |
2006-03-02 |
Ishikawa Muriel Y |
System and method for magnifying an immune response
|
US20060047434A1
(en)
*
|
2004-08-24 |
2006-03-02 |
Ishikawa Muriel Y |
System and method related to improving an immune system
|
US20060122783A1
(en)
*
|
2004-08-24 |
2006-06-08 |
Ishikawa Muriel Y |
System and method for heightening a humoral immune response
|
US20060116824A1
(en)
*
|
2004-12-01 |
2006-06-01 |
Ishikawa Muriel Y |
System and method for modulating a humoral immune response
|
US20060095211A1
(en)
*
|
2003-12-05 |
2006-05-04 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
System and method for modulating a cell mediated immune response
|
US20060047435A1
(en)
*
|
2004-08-24 |
2006-03-02 |
Ishikawa Muriel Y |
System and method related to augmenting an immune system
|
US20060047433A1
(en)
*
|
2004-08-24 |
2006-03-02 |
Ishikawa Muriel Y |
System and method related to enhancing an immune system
|
US20060182742A1
(en)
*
|
2004-08-24 |
2006-08-17 |
Ishikawa Muriel Y |
System and method for magnifying a humoral immune response
|
US20060122784A1
(en)
*
|
2004-12-03 |
2006-06-08 |
Ishikawa Muriel Y |
System and method for augmenting a humoral immune response
|
GB0328363D0
(en)
|
2003-12-06 |
2004-01-14 |
Imp College Innovations Ltd |
Therapeutically useful molecules
|
DE602005011617D1
(de)
|
2004-05-19 |
2009-01-22 |
Medigene Ltd |
Hochaffiner ny-eso-t-zellen-rezeptor
|
GB0411771D0
(en)
*
|
2004-05-26 |
2004-06-30 |
Avidex Ltd |
Nucleoproteins displaying native T cell receptor libraries
|
WO2005116075A1
(en)
*
|
2004-05-26 |
2005-12-08 |
Avidex Ltd. |
High affinity telomerase t cell receptors
|
GB0411773D0
(en)
*
|
2004-05-26 |
2004-06-30 |
Avidex Ltd |
Method for the identification of polypeptides which bind to a given peptide mhc complex or cd 1-antigen complex
|
EP2330121B1
(en)
*
|
2004-06-02 |
2014-09-03 |
AdAlta Pty Ltd |
Binding moieties based on Shark IgNAR domains
|
ATE475669T1
(de)
*
|
2004-06-29 |
2010-08-15 |
Immunocore Ltd |
Einen modifizierten t-zellen-rezeptor exprimierende zellen
|
US20070198196A1
(en)
*
|
2004-08-24 |
2007-08-23 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational systems and methods relating to ameliorating an immune system
|
US20070207492A1
(en)
*
|
2004-08-24 |
2007-09-06 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems to adjust a humoral immune response
|
US20060047439A1
(en)
*
|
2004-08-24 |
2006-03-02 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
System and method for improving a humoral immune response
|
US20070196362A1
(en)
*
|
2004-08-24 |
2007-08-23 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems to bolster an immune response
|
US20070265819A1
(en)
*
|
2004-08-24 |
2007-11-15 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems for improving cell-mediated immune response
|
US20070265818A1
(en)
*
|
2004-08-24 |
2007-11-15 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems for heightening cell-mediated immune response
|
AU2005291039A1
(en)
*
|
2004-10-01 |
2006-04-13 |
Avidex Ltd. |
T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
|
US20080274133A1
(en)
*
|
2004-11-18 |
2008-11-06 |
Avidex Ltd. |
Soluble Bifunctional Proteins
|
GB0425732D0
(en)
*
|
2004-11-23 |
2004-12-22 |
Avidex Ltd |
Gamma-delta t cell receptors
|
CA2594356C
(en)
|
2005-01-05 |
2018-07-17 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. |
Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
|
ES2599010T3
(es)
|
2005-04-01 |
2017-01-31 |
Immunocore Ltd. |
Receptores de linfocitos T con alta afinidad por el VIH
|
GB0524477D0
(en)
*
|
2005-11-30 |
2006-01-11 |
Avidex Ltd |
Isolated T cell receptors which specifically bind to vygfvracl-hla-24
|
GB0511124D0
(en)
|
2005-06-01 |
2005-07-06 |
Avidex Ltd |
High affinity melan-a t cell receptors
|
IN2014DN06624A
(es)
|
2005-10-18 |
2015-07-10 |
Univ Colorado |
|
US7820174B2
(en)
*
|
2006-02-24 |
2010-10-26 |
The United States Of America As Represented By The Department Of Health And Human Services |
T cell receptors and related materials and methods of use
|
AU2007266452A1
(en)
|
2006-05-31 |
2007-12-06 |
The Children's Hospital Of Philadelphia |
Compositions and methods for detection and modulation of T cell mediated immune responses against viral vectors utilized for gene therapy
|
AT503861B1
(de)
*
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von t-zell-rezeptoren
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
WO2008039818A2
(en)
|
2006-09-26 |
2008-04-03 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Modified t cell receptors and related materials and methods
|
WO2009000006A1
(en)
|
2007-06-26 |
2008-12-31 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. |
Display of binding agents
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
AU2009246876B2
(en)
|
2008-05-16 |
2015-04-02 |
Taiga Biotechnologies, Inc. |
Antibodies and processes for preparing the same
|
AU2009280012B2
(en)
*
|
2008-08-07 |
2012-12-06 |
Ipsen Pharma S.A.S. |
Truncated analogues of glucose-dependent insulinotropic polypeptide
|
DK2966084T3
(en)
|
2008-08-28 |
2018-08-06 |
Taiga Biotechnologies Inc |
MODULATORS OF MYC, PROCEDURES FOR USING SAME AND PROCEDURES FOR IDENTIFYING SUBSTANCES MODULATING MYC
|
US8748103B2
(en)
|
2008-11-07 |
2014-06-10 |
Sequenta, Inc. |
Monitoring health and disease status using clonotype profiles
|
US8628927B2
(en)
|
2008-11-07 |
2014-01-14 |
Sequenta, Inc. |
Monitoring health and disease status using clonotype profiles
|
EP4335932A2
(en)
|
2008-11-07 |
2024-03-13 |
Adaptive Biotechnologies Corporation |
Methods of monitoring conditions by sequence analysis
|
US9528160B2
(en)
|
2008-11-07 |
2016-12-27 |
Adaptive Biotechnolgies Corp. |
Rare clonotypes and uses thereof
|
US9506119B2
(en)
|
2008-11-07 |
2016-11-29 |
Adaptive Biotechnologies Corp. |
Method of sequence determination using sequence tags
|
US9365901B2
(en)
|
2008-11-07 |
2016-06-14 |
Adaptive Biotechnologies Corp. |
Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
|
EP2387627B1
(en)
|
2009-01-15 |
2016-03-30 |
Adaptive Biotechnologies Corporation |
Adaptive immunity profiling and methods for generation of monoclonal antibodies
|
WO2010088160A1
(en)
|
2009-01-28 |
2010-08-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell receptors and related materials and methods of use
|
GB0908613D0
(en)
*
|
2009-05-20 |
2009-06-24 |
Immunocore Ltd |
T Cell Reseptors
|
EP3409792B1
(en)
|
2009-06-25 |
2023-09-20 |
Fred Hutchinson Cancer Center |
Method of measuring adaptive immunity
|
GB0911566D0
(en)
|
2009-07-03 |
2009-08-12 |
Immunocore Ltd |
T cell receptors
|
CN102295702B
(zh)
*
|
2011-08-26 |
2014-01-29 |
中国科学院微生物研究所 |
一种针对t细胞受体可变区特异性单抗的制备方法
|
US10385475B2
(en)
|
2011-09-12 |
2019-08-20 |
Adaptive Biotechnologies Corp. |
Random array sequencing of low-complexity libraries
|
WO2013041865A1
(en)
|
2011-09-22 |
2013-03-28 |
Immunocore Limited |
T cell receptors
|
US9279159B2
(en)
|
2011-10-21 |
2016-03-08 |
Adaptive Biotechnologies Corporation |
Quantification of adaptive immune cell genomes in a complex mixture of cells
|
KR102148387B1
(ko)
|
2011-10-28 |
2020-08-26 |
리제너론 파아마슈티컬스, 인크. |
유전자 변형된 t 세포 수용체 마우스
|
CA2858070C
(en)
|
2011-12-09 |
2018-07-10 |
Adaptive Biotechnologies Corporation |
Diagnosis of lymphoid malignancies and minimal residual disease detection
|
US9499865B2
(en)
|
2011-12-13 |
2016-11-22 |
Adaptive Biotechnologies Corp. |
Detection and measurement of tissue-infiltrating lymphocytes
|
WO2013134162A2
(en)
|
2012-03-05 |
2013-09-12 |
Sequenta, Inc. |
Determining paired immune receptor chains from frequency matched subunits
|
CN104520440B
(zh)
|
2012-05-08 |
2017-10-03 |
适应生物技术公司 |
用于测量和校准多重pcr反应中的扩增偏倚的组合物和方法
|
WO2013177247A1
(en)
|
2012-05-22 |
2013-11-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Murine anti-ny-eso-1 t cell receptors
|
SG11201500429QA
(en)
|
2012-07-20 |
2015-03-30 |
Taiga Biotechnologies Inc |
Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
|
SG10201700442QA
(en)
*
|
2012-07-27 |
2017-03-30 |
Univ Illinois |
Engineering t-cell receptors
|
JP6449160B2
(ja)
|
2012-10-01 |
2019-01-09 |
アダプティブ バイオテクノロジーズ コーポレイション |
適応免疫受容体多様性およびクローン性特性決定による免疫能力評価関連出願の相互参照
|
TW202206465A
(zh)
|
2012-11-14 |
2022-02-16 |
美商再生元醫藥公司 |
重組細胞表面捕捉蛋白質
|
GB201223172D0
(en)
|
2012-12-21 |
2013-02-06 |
Immunocore Ltd |
Method
|
US10272115B2
(en)
|
2013-03-11 |
2019-04-30 |
Taiga Biotechnologies, Inc. |
Production and use of red blood cells
|
US9708657B2
(en)
|
2013-07-01 |
2017-07-18 |
Adaptive Biotechnologies Corp. |
Method for generating clonotype profiles using sequence tags
|
GB201313377D0
(en)
*
|
2013-07-26 |
2013-09-11 |
Adaptimmune Ltd |
T cell receptors
|
TR201908404T4
(tr)
*
|
2013-11-22 |
2019-07-22 |
Hutchinson Fred Cancer Res |
İşlenmiş yüksek afinite insan t hücresi reseptörleri.
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
WO2015095811A2
(en)
|
2013-12-20 |
2015-06-25 |
The Board Institute Inc. |
Combination therapy with neoantigen vaccine
|
GB201322798D0
(en)
|
2013-12-20 |
2014-02-05 |
Oxford Biomedica Ltd |
Production system
|
CA2941612A1
(en)
|
2014-03-05 |
2015-09-11 |
Adaptive Biotechnologies Corporation |
Methods using randomer-containing synthetic molecules
|
SG11201607181WA
(en)
|
2014-03-14 |
2016-09-29 |
Immunocore Ltd |
Tcr libraries
|
US10066265B2
(en)
|
2014-04-01 |
2018-09-04 |
Adaptive Biotechnologies Corp. |
Determining antigen-specific t-cells
|
US11390921B2
(en)
|
2014-04-01 |
2022-07-19 |
Adaptive Biotechnologies Corporation |
Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
|
EP3132059B1
(en)
|
2014-04-17 |
2020-01-08 |
Adaptive Biotechnologies Corporation |
Quantification of adaptive immune cell genomes in a complex mixture of cells
|
WO2016014725A1
(en)
|
2014-07-22 |
2016-01-28 |
The University Of Notre Dame Du Lac |
Molecular constructs and uses thereof
|
US9711252B1
(en)
|
2014-10-28 |
2017-07-18 |
Michelle Corning |
High energy beam diffraction material treatment system
|
US9938026B1
(en)
|
2014-10-28 |
2018-04-10 |
Michelle Corning |
Energy beam propulsion system
|
US10629318B1
(en)
|
2014-10-28 |
2020-04-21 |
Michelle Corning |
Neutron beam diffraction material treatment system
|
AU2015339191A1
(en)
|
2014-10-29 |
2017-05-18 |
Adaptive Biotechnologies Corp. |
Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
|
JP6770966B2
(ja)
*
|
2014-11-05 |
2020-10-21 |
ジェネンテック, インコーポレイテッド |
細菌における2鎖タンパク質の生成方法
|
AU2015342961B2
(en)
|
2014-11-05 |
2021-08-12 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
WO2016070814A1
(zh)
|
2014-11-07 |
2016-05-12 |
广州市香雪制药股份有限公司 |
一种可溶的异质二聚t细胞受体及其制法和应用
|
US10246701B2
(en)
|
2014-11-14 |
2019-04-02 |
Adaptive Biotechnologies Corp. |
Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
|
WO2016086029A1
(en)
|
2014-11-25 |
2016-06-02 |
Adaptive Biotechnologies Corporation |
Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
|
WO2016100975A1
(en)
|
2014-12-19 |
2016-06-23 |
Massachsetts Institute Ot Technology |
Molecular biomarkers for cancer immunotherapy
|
EP3757211A1
(en)
|
2014-12-19 |
2020-12-30 |
The Broad Institute, Inc. |
Methods for profiling the t-cell-receptor repertoire
|
CN105985427A
(zh)
*
|
2015-02-06 |
2016-10-05 |
广州市香雪制药股份有限公司 |
高亲和力ny-eso t细胞受体
|
WO2016138122A1
(en)
|
2015-02-24 |
2016-09-01 |
Adaptive Biotechnologies Corp. |
Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing
|
EP3277294B1
(en)
|
2015-04-01 |
2024-05-15 |
Adaptive Biotechnologies Corp. |
Method of identifying human compatible t cell receptors specific for an antigenic target
|
NZ736031A
(en)
|
2015-04-06 |
2022-07-29 |
Regeneron Pharma |
Humanized t cell mediated immune responses in non-human animals
|
CN106279404A
(zh)
*
|
2015-05-20 |
2017-01-04 |
广州市香雪制药股份有限公司 |
一种可溶且稳定的异质二聚tcr
|
KR20180010229A
(ko)
|
2015-05-20 |
2018-01-30 |
더 브로드 인스티튜트, 인코퍼레이티드 |
공유 신생항원
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
US10166255B2
(en)
|
2015-07-31 |
2019-01-01 |
Regents Of The University Of Minnesota |
Intracellular genomic transplant and methods of therapy
|
EP3347374A1
(en)
|
2015-09-09 |
2018-07-18 |
Immune Design Corp. |
Ny-eso-1 specific tcrs and methods of use thereof
|
GB201516272D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516277D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR libraries
|
GB201516274D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516270D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516265D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516269D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516275D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
CA2999888C
(en)
|
2015-09-24 |
2024-04-09 |
Abvitro Llc |
Affinity-oligonucleotide conjugates and uses thereof
|
CN113774495A
(zh)
|
2015-09-25 |
2021-12-10 |
阿布维特罗有限责任公司 |
用于对天然配对t细胞受体序列进行t细胞受体靶向鉴别的高通量方法
|
US20190255107A1
(en)
|
2015-10-09 |
2019-08-22 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
EP3368689B1
(en)
|
2015-10-28 |
2020-06-17 |
The Broad Institute, Inc. |
Composition for modulating immune responses by use of immune cell gene signature
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
WO2017087708A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
GB201520563D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201607535D0
(en)
|
2016-04-29 |
2016-06-15 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520546D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520557D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520536D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520589D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520595D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520597D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520543D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201604468D0
(en)
|
2016-03-16 |
2016-04-27 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520542D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520570D0
(en)
*
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520550D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520539D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201607534D0
(en)
|
2016-04-29 |
2016-06-15 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520579D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520559D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
WO2017089786A1
(en)
|
2015-11-23 |
2017-06-01 |
Immunocore Limited |
Peptides
|
GB201520541D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520592D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520583D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520575D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520565D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520564D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520566D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520603D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520562D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520567D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520544D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520568D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd |
Peptides
|
GB201520548D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520545D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520558D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201522592D0
(en)
|
2015-12-22 |
2016-02-03 |
Immunocore Ltd |
T cell receptors
|
AU2017206656B2
(en)
|
2016-01-10 |
2024-02-01 |
Neotx Therapeutics Ltd. |
Immunopotentiator enhanced superantigen mediated cancer immunotherapy
|
GB201604953D0
(en)
|
2016-03-23 |
2016-05-04 |
Immunocore Ltd |
T cell receptors
|
RU2018138838A
(ru)
|
2016-04-08 |
2020-05-14 |
Адаптимьюн Лимитед |
Т-клеточные рецепторы
|
CA3020530A1
(en)
|
2016-04-08 |
2017-10-12 |
Adaptimmune Limited |
T cell receptors
|
RS63371B1
(sr)
|
2016-04-08 |
2022-08-31 |
Immunocore Ltd |
T ćelijski receptori
|
CA3020555A1
(en)
|
2016-04-08 |
2017-10-12 |
Adaptimmune Limited |
T cell receptors
|
CN109312402A
(zh)
*
|
2016-04-11 |
2019-02-05 |
得克萨斯州大学***董事会 |
用于检测单个t细胞受体亲和力和序列的方法和组合物
|
AU2017254477A1
(en)
|
2016-04-18 |
2018-11-01 |
Jennifer G. ABELIN |
Improved HLA epitope prediction
|
US11827688B2
(en)
|
2016-06-02 |
2023-11-28 |
Immunocore Limited |
Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion protein
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
US20200182884A1
(en)
|
2016-06-27 |
2020-06-11 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
US11630103B2
(en)
|
2016-08-17 |
2023-04-18 |
The Broad Institute, Inc. |
Product and methods useful for modulating and evaluating immune responses
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
US10428325B1
(en)
|
2016-09-21 |
2019-10-01 |
Adaptive Biotechnologies Corporation |
Identification of antigen-specific B cell receptors
|
BR112019005748A2
(pt)
|
2016-09-24 |
2019-06-18 |
Abvitro Llc |
afinidade-conjugados de oligonucleotídeo e usos destes
|
EP3519433A1
(en)
|
2016-10-03 |
2019-08-07 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
CA3039812A1
(en)
*
|
2016-10-11 |
2018-04-19 |
Bluebird Bio, Inc. |
Tcr.alpha. homing endonuclease variants
|
MA46649A
(fr)
|
2016-10-13 |
2019-08-21 |
Juno Therapeutics Inc |
Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane
|
CN110520530A
(zh)
|
2016-10-18 |
2019-11-29 |
明尼苏达大学董事会 |
肿瘤浸润性淋巴细胞和治疗方法
|
US20190292246A1
(en)
|
2016-11-03 |
2019-09-26 |
Juno Therapeutics, Inc. |
Combination therapy of a cell based therapy and a microglia imhibitor
|
JP2019532997A
(ja)
|
2016-11-03 |
2019-11-14 |
ジュノー セラピューティクス インコーポレイテッド |
T細胞療法とbtk阻害剤との併用療法
|
US20210115099A1
(en)
|
2016-11-07 |
2021-04-22 |
Immunocore Limited |
Peptides
|
KR20190092472A
(ko)
|
2016-12-02 |
2019-08-07 |
타이가 바이오테크놀로지스, 인코포레이티드 |
나노입자 제제
|
CA3045355A1
(en)
|
2016-12-03 |
2018-06-07 |
Juno Therapeutics, Inc. |
Methods for determining car-t cells dosing
|
US11590167B2
(en)
|
2016-12-03 |
2023-02-28 |
Juno Therapeutic, Inc. |
Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
|
MX2019006285A
(es)
|
2016-12-03 |
2019-12-16 |
Juno Therapeutics Inc |
Metodos para modulacion de celulas cart-t.
|
US20190350978A1
(en)
|
2016-12-05 |
2019-11-21 |
Juno Therapeutics, Inc. |
Production of engineered cells for adoptive cell therapy
|
US11821027B2
(en)
|
2017-01-10 |
2023-11-21 |
Juno Therapeutics, Inc. |
Epigenetic analysis of cell therapy and related methods
|
CA3049016A1
(en)
|
2017-01-13 |
2018-07-19 |
Agenus Inc. |
T cell receptors that bind to ny-eso-1 and methods of use thereof
|
MA47325A
(fr)
|
2017-01-20 |
2019-11-27 |
Juno Therapeutics Gmbh |
Conjugués de surface cellulaire et compositions cellulaires et méthodes associées
|
EP3574116A1
(en)
|
2017-01-24 |
2019-12-04 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
WO2018140427A1
(en)
|
2017-01-25 |
2018-08-02 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
|
WO2018148180A2
(en)
|
2017-02-07 |
2018-08-16 |
Immune Design Corp. |
Materials and methods for identifying and treating cancer patients
|
US11965892B2
(en)
|
2017-02-12 |
2024-04-23 |
Biontech Us Inc. |
HLA-based methods and compositions and uses thereof
|
AU2018222749B2
(en)
|
2017-02-17 |
2024-04-18 |
Fred Hutchinson Cancer Center |
Combination therapies for treatment of BCMA-related cancers and autoimmune disorders
|
CN110582287A
(zh)
|
2017-02-27 |
2019-12-17 |
朱诺治疗学股份有限公司 |
与在细胞疗法中给药有关的组合物、制品和方法
|
EP3595440A2
(en)
|
2017-03-14 |
2020-01-22 |
Juno Therapeutics, Inc. |
Methods for cryogenic storage
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
EP3606518A4
(en)
|
2017-04-01 |
2021-04-07 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
|
US20230190796A1
(en)
|
2017-04-07 |
2023-06-22 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
|
EP3610266A4
(en)
|
2017-04-12 |
2021-04-21 |
Massachusetts Eye and Ear Infirmary |
TUMOR SIGNATURE OF METASTASIS, COMPOSITIONS OF SUBSTANCES AND USES THEREOF
|
US11796534B2
(en)
|
2017-04-14 |
2023-10-24 |
Juno Therapeutics, Inc. |
Methods for assessing cell surface glycosylation
|
WO2018195019A1
(en)
|
2017-04-18 |
2018-10-25 |
The Broad Institute Inc. |
Compositions for detecting secretion and methods of use
|
WO2018204427A1
(en)
|
2017-05-01 |
2018-11-08 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and an immunomodulatory compound
|
CN111148849A
(zh)
|
2017-05-26 |
2020-05-12 |
阿布维托有限责任公司 |
高通量多核苷酸文库测序和转录组分析
|
JP2020522489A
(ja)
|
2017-06-02 |
2020-07-30 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法を用いる処置のための製造物品および方法
|
US11740231B2
(en)
|
2017-06-02 |
2023-08-29 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods related to toxicity associated with cell therapy
|
EP3638218A4
(en)
|
2017-06-14 |
2021-06-09 |
The Broad Institute, Inc. |
COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
|
GB201709866D0
(en)
|
2017-06-20 |
2017-08-02 |
Immunocore Ltd |
T cell receptors
|
CA3067602A1
(en)
|
2017-06-29 |
2019-01-03 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
WO2019006418A2
(en)
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
MX2020000900A
(es)
|
2017-07-29 |
2021-01-08 |
Juno Therapeutics Inc |
Reactivos para expandir celulas que expresan receptores recombinantes.
|
CN115028739A
(zh)
|
2017-08-03 |
2022-09-09 |
泰加生物工艺学公司 |
用于治疗黑素瘤的方法和组合物
|
US10149898B2
(en)
|
2017-08-03 |
2018-12-11 |
Taiga Biotechnologies, Inc. |
Methods and compositions for the treatment of melanoma
|
CA3070575A1
(en)
|
2017-08-09 |
2019-02-14 |
Juno Therapeutics, Inc. |
Methods and compositions for preparing genetically engineered cells
|
US11851678B2
(en)
|
2017-08-09 |
2023-12-26 |
Juno Therapeutics, Inc. |
Methods for producing genetically engineered cell compositions and related compositions
|
EP3676403A1
(en)
|
2017-09-01 |
2020-07-08 |
Juno Therapeutics, Inc. |
Gene expression and assessment of risk of developing toxicity following cell therapy
|
EP3679062A1
(en)
|
2017-09-04 |
2020-07-15 |
Agenus Inc. |
T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
|
EP3679370A1
(en)
|
2017-09-07 |
2020-07-15 |
Juno Therapeutics, Inc. |
Methods of identifying cellular attributes related to outcomes associated with cell therapy
|
KR20200066616A
(ko)
|
2017-09-21 |
2020-06-10 |
더 브로드 인스티튜트, 인코퍼레이티드 |
표적화된 핵산 편집을 위한 시스템, 방법 및 조성물
|
JP7387611B2
(ja)
|
2017-09-22 |
2023-11-28 |
ウーシー バイオロジクス アイルランド リミテッド |
新規二重特異性ポリペプチド複合体
|
AU2018337142A1
(en)
|
2017-09-22 |
2020-05-07 |
Wuxi Biologics Ireland Limited. |
Novel bispecific CD3/CD19 polypeptide complexes
|
SG11202002728VA
(en)
|
2017-10-03 |
2020-04-29 |
Juno Therapeutics Inc |
Hpv-specific binding molecules
|
WO2019084055A1
(en)
|
2017-10-23 |
2019-05-02 |
Massachusetts Institute Of Technology |
CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
|
EP3704229B1
(en)
|
2017-11-01 |
2023-12-20 |
Juno Therapeutics, Inc. |
Process for producing a t cell composition
|
US20210132042A1
(en)
|
2017-11-01 |
2021-05-06 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
US11564946B2
(en)
|
2017-11-01 |
2023-01-31 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
US11851679B2
(en)
|
2017-11-01 |
2023-12-26 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
MX2020004240A
(es)
|
2017-11-01 |
2020-09-25 |
Juno Therapeutics Inc |
Proceso para generar composiciones terapeuticas de celulas modificadas.
|
BR112020008812A2
(pt)
|
2017-11-06 |
2020-10-27 |
Juno Therapeutics Inc |
combinação de terapia celular e um inibidor de gama secretase
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
EP3714041A1
(en)
|
2017-11-22 |
2020-09-30 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
US11254980B1
(en)
|
2017-11-29 |
2022-02-22 |
Adaptive Biotechnologies Corporation |
Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
|
WO2019109053A1
(en)
|
2017-12-01 |
2019-06-06 |
Juno Therapeutics, Inc. |
Methods for dosing and for modulation of genetically engineered cells
|
JP2021505168A
(ja)
|
2017-12-08 |
2021-02-18 |
ジュノー セラピューティクス インコーポレイテッド |
操作されたt細胞の組成物を製造するための方法
|
EP3720480A2
(en)
|
2017-12-08 |
2020-10-14 |
Juno Therapeutics, Inc. |
Phenotypic markers for cell therapy and related methods
|
CN112041430A
(zh)
|
2017-12-08 |
2020-12-04 |
朱诺治疗学股份有限公司 |
用于培养细胞的无血清培养基配制品及其使用方法
|
JPWO2019151392A1
(ja)
*
|
2018-01-31 |
2021-02-04 |
国立大学法人東北大学 |
抗原特異的mhc発現調節法
|
US20210069246A1
(en)
|
2018-01-31 |
2021-03-11 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
CN111819194A
(zh)
|
2018-02-26 |
2020-10-23 |
基因医疗免疫疗法有限责任公司 |
Nyeso t细胞受体(tcr)
|
PE20201345A1
(es)
|
2018-04-05 |
2020-11-25 |
Juno Therapeutics Inc |
Receptores de celulas t, y celulas disenadas que expresan los mismos
|
EP3775238A1
(en)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics, Inc. |
Methods of producing cells expressing a recombinant receptor and related compositions
|
CA3095084A1
(en)
|
2018-04-05 |
2019-10-10 |
Juno Therapeutics, Inc. |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
KR20210010896A
(ko)
|
2018-05-14 |
2021-01-28 |
이뮤노코어 리미티드 |
이기능성 결합 폴리펩타이드
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
US20210300987A1
(en)
|
2018-08-06 |
2021-09-30 |
Medigene Immunotherapies Gmbh |
Ha-1 specific t cell receptors and their use
|
CN110818802B
(zh)
*
|
2018-08-08 |
2022-02-08 |
华夏英泰(北京)生物技术有限公司 |
一种嵌合t细胞受体star及其应用
|
SG11202101130VA
(en)
|
2018-08-09 |
2021-03-30 |
Juno Therapeutics Inc |
Methods for assessing integrated nucleic acids
|
KR20210057730A
(ko)
|
2018-08-09 |
2021-05-21 |
주노 쎄러퓨티크스 인코퍼레이티드 |
조작 세포 및 이의 조성물 생성 방법
|
US20210177832A1
(en)
|
2018-08-20 |
2021-06-17 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease target binding and uses thereof
|
WO2020041384A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
|
WO2020041387A1
(en)
|
2018-08-20 |
2020-02-27 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
BR112021004261A2
(pt)
|
2018-09-11 |
2021-05-25 |
Juno Therapeutics Inc |
métodos para análise por espectrometria de massas de composições de células geneticamente modificadas
|
GB201815041D0
(en)
|
2018-09-14 |
2018-10-31 |
Scancell Ltd |
Epitopes
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
SG11202104355SA
(en)
|
2018-10-31 |
2021-05-28 |
Juno Therapeutics Gmbh |
Methods for selection and stimulation of cells and apparatus for same
|
EP3877054B1
(en)
|
2018-11-06 |
2023-11-01 |
Juno Therapeutics, Inc. |
Process for producing genetically engineered t cells
|
CN113573719A
(zh)
|
2018-11-08 |
2021-10-29 |
朱诺治疗学股份有限公司 |
治疗和t细胞调节的方法和组合
|
US20220088070A1
(en)
|
2018-11-30 |
2022-03-24 |
Juno Therapeutics, Inc. |
Methods for treatment using adoptive cell therapy
|
EP3886894B1
(en)
|
2018-11-30 |
2024-03-13 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
BR112021012278A2
(pt)
|
2018-12-21 |
2021-12-14 |
Biontech Us Inc |
Método e sistema para a preparação de células hla de classe ii-específica de epitopes e de síntese de cd4 + t
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
***新抗原及其用途
|
LT3911298T
(lt)
|
2019-01-17 |
2023-12-27 |
Immunocore Limited |
Kompozicijos
|
WO2020156405A1
(en)
*
|
2019-01-28 |
2020-08-06 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel bispecific cd3/cd20 polypeptide complexes
|
GB201901305D0
(en)
|
2019-01-30 |
2019-03-20 |
Immunocore Ltd |
Specific binding molecules
|
GB201901306D0
(en)
|
2019-01-30 |
2019-03-20 |
Immunocore Ltd |
Multi-domain binding molecules
|
KR20210136050A
(ko)
|
2019-03-01 |
2021-11-16 |
이오반스 바이오테라퓨틱스, 인크. |
액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
WO2020188348A2
(en)
|
2019-03-18 |
2020-09-24 |
Ludwig Institute For Cancer Research Ltd |
A2/ny-eso-1 specific t cell receptors and uses thereof
|
EP3714941A1
(en)
|
2019-03-27 |
2020-09-30 |
Medigene Immunotherapies GmbH |
Mage-a4 tcrs
|
GB201904328D0
(en)
|
2019-03-28 |
2019-05-15 |
Immunocore Ltd |
Specific binding molecules
|
TW202102530A
(zh)
|
2019-04-04 |
2021-01-16 |
德商梅迪基因免疫治療公司 |
黑色素瘤相關抗原1(magea1)特異性t細胞受體及其用途
|
BR112021021075A2
(pt)
|
2019-05-01 |
2021-12-14 |
Editas Medicine Inc |
Células que expressam um receptor recombinante de um locus de tgfbr2 modificado, polinucleotídeos relacionados e métodos
|
MX2021013908A
(es)
|
2019-05-15 |
2022-03-11 |
Neotx Therapeutics Ltd |
Tratamiento para el cáncer.
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
US20220226464A1
(en)
|
2019-05-28 |
2022-07-21 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
MX2021015125A
(es)
|
2019-06-07 |
2022-04-06 |
Juno Therapeutics Inc |
Cultivo automatizado de celulas t.
|
CA3142361A1
(en)
|
2019-06-12 |
2020-12-17 |
Juno Therapeutics, Inc. |
Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
|
EP3997116A1
(en)
|
2019-07-09 |
2022-05-18 |
Medigene Immunotherapies GmbH |
Magea10 specific t cell receptors and their use
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
KR20220066892A
(ko)
|
2019-08-22 |
2022-05-24 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 요법 및 제스트 동족체 2의 인핸서 (ezh2) 억제제의 병용 요법 및 관련 방법
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
CN114502578A
(zh)
|
2019-09-06 |
2022-05-13 |
伊莱利利公司 |
包含t-细胞受体恒定结构域的蛋白
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
GB201915282D0
(en)
|
2019-10-22 |
2019-12-04 |
Immunocore Ltd |
Specific binding molecules
|
JP2023500318A
(ja)
|
2019-10-30 |
2023-01-05 |
ジュノ セラピューティクス ゲーエムベーハー |
細胞選択および/または細胞刺激デバイスならびに使用方法
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
CN114667161A
(zh)
|
2019-11-12 |
2022-06-24 |
牛津生物医学(英国)有限公司 |
生产***
|
EP4061405A1
(en)
|
2019-11-18 |
2022-09-28 |
Janssen Biotech, Inc. |
Vaccines based on mutant calr and jak2 and their uses
|
AU2020395318A1
(en)
|
2019-12-06 |
2022-06-09 |
Juno Therapeutics, Inc. |
Methods related to toxicity and response associated with cell therapy for treating B cell malignancies
|
US11865168B2
(en)
|
2019-12-30 |
2024-01-09 |
Massachusetts Institute Of Technology |
Compositions and methods for treating bacterial infections
|
WO2021154887A1
(en)
|
2020-01-28 |
2021-08-05 |
Juno Therapeutics, Inc. |
Methods for t cell transduction
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
CN115484978A
(zh)
|
2020-03-05 |
2022-12-16 |
尼奥克斯医疗有限公司 |
使用免疫细胞治疗癌症的方法和组合物
|
WO2021190580A1
(en)
*
|
2020-03-26 |
2021-09-30 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Bispecific polypeptide complexes, compositions, and methods of preparation and use
|
GB202005779D0
(en)
|
2020-04-21 |
2020-06-03 |
Scancell Ltd |
Anti-tumour immune responses
|
CA3174332A1
(en)
|
2020-04-21 |
2021-10-28 |
Jason PERERA |
Tcr/bcr profiling
|
GB202006629D0
(en)
|
2020-05-05 |
2020-06-17 |
Immunocore Ltd |
Specific binding molecules
|
KR20230022868A
(ko)
|
2020-05-13 |
2023-02-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
|
US20230178239A1
(en)
|
2020-05-13 |
2023-06-08 |
Juno Therapeutics, Inc. |
Methods of identifying features associated with clinical response and uses thereof
|
EP4171616A1
(en)
|
2020-06-26 |
2023-05-03 |
Juno Therapeutics GmbH |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
GB202010329D0
(en)
|
2020-07-06 |
2020-08-19 |
Immunocore Ltd |
Specific binding molecules
|
WO2022060904A1
(en)
|
2020-09-16 |
2022-03-24 |
Obsidian Therapeutics, Inc. |
Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
|
US20230340064A1
(en)
|
2020-09-24 |
2023-10-26 |
Medigene Immunotherapies Gmbh |
Mage-a3 specific t cell receptors and their use
|
GB202018395D0
(en)
|
2020-11-23 |
2021-01-06 |
Scancell Ltd |
Immunotherapy
|
KR20230112654A
(ko)
|
2020-11-24 |
2023-07-27 |
상하이 젠베이스 바이오테크놀로지 씨오., 엘티디. |
Ras 돌연변이 에피토프 펩티드 및 ras 돌연변이체를 인식하는 t 세포 수용체
|
GB202019019D0
(en)
|
2020-12-02 |
2021-01-13 |
Univ Oxford Innovation Ltd |
T cell receptors and uses thereof
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
WO2022140759A2
(en)
|
2020-12-23 |
2022-06-30 |
Janssen Biotech, Inc. |
Neoantigen peptide mimics
|
KR20230133878A
(ko)
*
|
2021-01-19 |
2023-09-19 |
우시 바이올로직스 아일랜드 리미티드 |
안정성 및 발현이 향상된 폴리펩티드 복합체
|
JP2024508725A
(ja)
|
2021-02-10 |
2024-02-28 |
上海吉倍生物技術有限公司 |
Ras g13d変異体のエピトープペプチド及びras g13d変異体を認識するt細胞受容体
|
JP2024507929A
(ja)
|
2021-02-25 |
2024-02-21 |
アラウノス セラピューティクス インコーポレイテッド |
多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
|
WO2022187280A1
(en)
|
2021-03-01 |
2022-09-09 |
Dana-Farber Cancer Institute, Inc. |
Personalized redirection and reprogramming of t cells for precise targeting of tumors
|
KR20230165771A
(ko)
|
2021-03-03 |
2023-12-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 요법 및 dgk 억제제의 조합
|
CN117321417A
(zh)
|
2021-03-22 |
2023-12-29 |
朱诺治疗学股份有限公司 |
确定治疗性细胞组合物的效力的方法
|
WO2022212400A1
(en)
|
2021-03-29 |
2022-10-06 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
IL308257A
(en)
|
2021-05-05 |
2024-01-01 |
Immatics Biotechnologies Gmbh |
Antigen binding proteins that uniquely bind PRAME
|
CN117916256A
(zh)
|
2021-05-06 |
2024-04-19 |
朱诺治疗学有限公司 |
用于刺激和转导t细胞的方法
|
EP4370540A2
(en)
|
2021-07-12 |
2024-05-22 |
Ludwig Institute for Cancer Research Ltd |
T cell receptors specific for tumor-associated antigens and methods of use thereof
|
WO2023099606A1
(en)
|
2021-12-01 |
2023-06-08 |
Immunocore Limited |
Treatment of mage-a4 positive cancer
|
WO2023099622A1
(en)
|
2021-12-01 |
2023-06-08 |
Immunocore Limited |
Treatment
|
WO2023147515A1
(en)
|
2022-01-28 |
2023-08-03 |
Juno Therapeutics, Inc. |
Methods of manufacturing cellular compositions
|
WO2023150562A1
(en)
|
2022-02-01 |
2023-08-10 |
Alaunos Therapeutics, Inc. |
Methods for activation and expansion of t cells
|
WO2023156663A1
(en)
|
2022-02-20 |
2023-08-24 |
Immunocore Limited |
Hiv-specific binding molecules and tcr
|
WO2023183344A1
(en)
|
2022-03-21 |
2023-09-28 |
Alaunos Therapeutics, Inc. |
Methods for identifying neoantigen-reactive t cell receptors
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
US20240092859A1
(en)
|
2022-08-18 |
2024-03-21 |
Immunocore Ltd |
T cell receptors and fusion proteins thereof
|
WO2024038183A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Limited |
Multi-domain binding molecules
|
WO2024038193A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Limited |
Multi-domain binding molecules
|
WO2024038198A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Limited |
Multi-domain binding molecules
|
WO2024050399A1
(en)
|
2022-09-01 |
2024-03-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
|
WO2024054944A1
(en)
|
2022-09-08 |
2024-03-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|